Lubna Choudhury

Lubna Choudhury

Cardiology

675 N St Clair St Ste 19-100
Galter Pavilion
Chicago, IL 60611

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 51 publications

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Effect of Aficamten on Cardiac Structure and Function in Patients with Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Journal: Circulation

Published: August 29, 2026

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy.

Journal: The New England journal of medicine

Published: August 28, 2026

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.

Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM.

Journal: Circulation

Published: August 28, 2026

Four-Chamber Deformation Remodeling and Atrial Fibrillation After Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy.

Four-Chamber Deformation Remodeling and Atrial Fibrillation After Septal Myectomy for Obstructive Hypertrophic Cardiomyopathy.

Journal: Echocardiography (Mount Kisco, N.Y.)

Published: May 18, 2026

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

Predictors of Long-Term Outcomes in Hypertrophic Cardiomyopathy: The NHLBI HCM Registry.

Journal: JAMA

Published: May 11, 2026

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy.

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy.

Journal: Journal of cardiovascular development and disease

Published: December 03, 2025

Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.

Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.

Journal: Journal of cardiac failure

Published: October 16, 2025

Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.

Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study.

Journal: medRxiv : the preprint server for health sciences

Published: September 26, 2025

Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy.

Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy.

Journal: Circulation

Published: September 22, 2025

Effect of Mavacamten on Serial Speckle-Tracking Strain in Patients with Hypertrophic Cardiomyopathy.

Effect of Mavacamten on Serial Speckle-Tracking Strain in Patients with Hypertrophic Cardiomyopathy.

Journal: Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography

Published: August 20, 2025

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

Aficamten in symptomatic obstructive hypertrophic cardiomyopathy: the FOREST-HCM long-term study.

Journal: European heart journal

Published: July 30, 2025

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.

Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM.

Journal: Journal of cardiac failure

Published: July 23, 2025

Showing 1-12 of 51

Last Updated: 09/26/2026